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Abstract 
Lignans, natural phytoestrogens found in flaxseed, have garnered increased attention due 
to their documented capabilities of inhibiting breast cancer development.  However, to what 
extent and the specific mechanisms by which lignans inhibit cancer growth is still subject to 
scrutiny.  Secoisolariciresinol diglucoside (SDG), a type of lignan that has not been thoroughly 
studied, was combined with tamoxifen (TAM) and administered to T47D breast cancer cells to 
investigate its anti-proliferative effects and its interactions with the well-known cancer therapy 
drug.  Results showed that SDG alone, TAM alone, and SDG combined with TAM significantly 
reduced T47D proliferation in comparison to untreated cells, and luminescence data showed that 
SDG was acting through the estrogenic pathway.  Significant decrease in T47D cell count also 
hinted at the possibility of SDG and TAM acting through the apoptosis pathway, but further 
experimentation is required to support this theory. 
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1. Introduction 
 Phytoestrogens found in the vegetarian/soy diet have sparked an interest in the general 
public due to their promising inhibitory effects on breast cancer.  Recent epidemiological studies 
have demonstrated that the soy-rich diet in Asian populations may be a critical factor in their 
respective low breast cancer incidence rates (Lamartiniere 2000).  Further clinical studies 
suggest that phytoestrogens, especially when combined with other breast cancer therapies such 
as tamoxifen, may have inhibitory effects on cell growth (Nurrochmad et. al, 2013, van Duursen 
et. al, 2013).  
 Phytoestrogens share similar structural properties with mammalian estrogen 17-
oestradiol, enabling them to bind to estrogen receptors and mimic their effects.  Their mechanism 
of action, although not entirely understood, relies on phytoestrogens binding to either ER-α or 
ER-β, and thus preventing the binding of estrogen, the natural driver of breast cancer (Velentzis 
et. al, 2008).  This would label phytoestrogens generally as estrogen receptor antagonists.  
Researchers have tried to combine plant-derived phytoestrogens and tamoxifen therapies to 
combat cancer proliferation, but results have varied. 
 Nurrochmad et. al, (2013) showed that low doses of phytoestrogen (8,9)-furanyl-
pterocarpan-3-ol (FPC), co-administered with a low dose of tamoxifen, showed proliferative 
effects on T47D breast cancer cells, compared to inhibitory effects at higher doses and simply 
tamoxifen alone.  A similar study testing against MCF-7 cells also found that four different 
phytoestrogens, along with genistein, had proliferative effects when combined with Letrozole 
(aromatase inhibitor) and tamoxifen (estrogen receptor antagonist) (van Duursen et. al, 2013).  
Interestingly, other studies suggest that lignans (a plant derived phytoestrogen) in flaxseed 
combined with tamoxifen have an inhibitory effect on breast cancer cells (Chen and Thompson 
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2003, Lindahl et. al, 2011, Thompson et. al, 2004).  Another study suggests that at higher doses, 
combination therapy of genistein (a phytoestrogen) and tamoxifen has inhibitory effects, but has 
proliferative effects at low dosages (Liu et. al, 2005).  It is clear that there is some relevance to 
the use of phytoestrogens in combination with preexisting synthetic cancer therapy drugs, such 
as tamoxifen.  
 Tamoxifen (TAM) is a non-steroidal drug that has both estrogenic and antiestrogenic 
effects, depending on the type of tissue that is being targeted.  Therefore, it is appropriate to refer 
to TAM as an “selective estrogen receptor modulator” (SERM).  In the case of breast tissue, it 
exhibits an antiestrogenic effect, so it is frequently used as a treatment for breast cancer tumors 
which express estrogen receptors in their cytoplasm.  The mechanism of action of TAM works in 
several ways.  For example, it acts as a competitive estrogen receptor antagonist (on both ER-α 
and ER-β receptors) with very similar affinities, meaning it inhibits the binding of estrogen to 
these receptors and therefore suppresses cellular proliferation.  The only difference between ER-
α and ER-β is that they may induce different effects depending which agonist it binds to; 
however, it has been shown that TAM induces an inhibitory effect when bound to either receptor 
(Helguero, 2005). Once the drug binds to the receptor, it recruits other molecules such as 
corepressor proteins to the site, which modulate gene expression in the cell’s DNA.  It also halts 
metastatic cell growth in the G0 and G1 phases of the cell cycle while preventing precancerous 
cells from dividing, without killing them (Sporn, 1970). 
 Few studies about lignans and their interactions with tamoxifen exist, so it is difficult to 
make significant conclusions.  This study attempts to shed light on the previous conflicting 
results, while also detailing if and how lignans may be used in combination therapies for breast 
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cancer.  It will also be useful to understand the exact mechanism of action of inhibition by 
lignans on breast cancer cells. 
 Secoisolariciresinol diglucoside (SDG), a type of lignan found in flaxseed, will be tested 
against T47D breast cancer cells, both alone and in combination with tamoxifen, to observe 
potential effects through regulation of estrogen receptors.  We hypothesize that a combination 
therapy of TAM and SDG will enhance the inhibitory effects of TAM, by downregulation of ER-
α or ER-β.  
 
2. Materials and Methods 
2.1 Cell Lines 
T47D cells, a breast cancer epithelial cell line expressing both estrogen receptors  and  
were used as a model system to analyze the effects of tamoxifen and SDG on cell proliferation. 
T47D K-Bluc cells are T47D cells stably transfected with a reporter plasmid containing three 
estrogen response elements upstream of a luciferase reporter (Wilson et. al, 2004).  These cells 
were used to examine the binding of Tamoxifen and SDG to estrogen receptors, due to their 
fluorescent behavior when activated at their receptor.  
2.2 Cell Maintenance 
T47D and T47D KBluc cells were grown in 89% Dulbecco's Modified Eagle Medium 
(DMEM), 10% fetal bovine serum (FBS—composed of ≤1 mg/mL bovine immunoglobulin and 
≤20 mg/mL hemoglobin), and 1% penicillin-streptomycin (PS, 5,000 units/mL penicillin and 5 
mg/mL streptomycin).  The cells were plated onto a T75 flask and incubated at 37°C, 5% CO2.  
They were fed approximately every 2 days and split at a 1:2 or 1:3 ratio approximately every 5 
days once confluence was observed.  Splitting of the cells required the use of trypsin because 
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they are adherent to the flask and to each other. To split cells, the medium was aspirated, and the 
flask was rinsed with phosphate buffered saline (PBS). 1 mL of 0.05% trypsin-EDTA was added 
and cells were incubated at 37℃ until cells began to lift from the flask. Cells were then washed 
from the flask surface in culture medium, centrifuged to pellet and resuspended for plating in 
culture medium. As necessary, cell counting was performed prior to plating. 
2.3 Cell Counts: 
Cells were counted using the trypan blue dye exclusion test to determine total cell count 
and viability using a Neubauer hemocytometer.  Alternatively, cells were counted in a 
Cellometer Auto T4 Cell Counter (Nexelcom) following manufacturer’s directions.  
2.4 Cell Plating  
 50,000 T47D cells were plated in each well of a 24-well plate in phenol-red DMEM, and 
were incubated for 2 days.  The media was then aspirated and replaced with phenol red-free, 
charcoal stripped media, in which the FBS component is removed of lipid-related materials, 
including steroids (Thermo Fisher Scientific Inc., 2020).  The cells were incubated again for 24 
hours before drug treatments in triplicates were added.  All drug treatments were left to incubate 
for 72 hours before cells were then aspirated, washed with PBS, and trypsinized for cell 
counting.  
 For luciferase assays, each well of a black, clear-bottomed 96-well plate contained 
30,000 T47D-KBluc cells in phenol-red DMEM, which were left to incubate for 2 days.  The 
media was then aspirated and replaced with phenol red-free, charcoal stripped media and 
incubated again for 24 hours before drug treatments were added.  All drug treatments were left to 
incubate for 72 hours before they were aspirated off, followed by the addition of 100 uL of ONE-
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Step luciferase reagent (mixture of 100 uL luciferase assay substrate and 10 mL buffer) (BPS 
Bioscience Inc., 2020).  Luminescence was recorded using a Victor3TM plate reader.  
2.4(a) Estrogen 
 A 20 ug/mL stock solution was created by combining 1 mg of -estradiol-17 (E2) with 1 
mL of absolute ethanol and 49 mL of sterile medium. The stock solution was held in dark storage 
at -20°C in 1 mL aliquots. Aliquots were diluted to a final concentration of 20nM and 
administered in each experiment to appropriate wells.  
Serial dilutions were performed to decrease the concentration of -estradiol (E2) in each 
well by a factor of 10 with each dilution, for a total of 5 different concentrations, starting at the 
physiological concentration of 20 nM and reaching the minimum 0.2 pM.  The concentration of 
20 nM was determined to be optimal based on previous research of physiological β-estradiol 
concentrations (Celojevic et al., 2011).  5 uL of each E2 concentration was added to their 
subsequent wells, each containing 50,000 cells/mL of phenol red-free, charcoal stripped DMEM, 
and pipetted up and down to ensure even distribution.  
2.4(b) Tamoxifen 
A stock solution of tamoxifen (TAM) and ethanol (1 mg/mL) was held in dark storage at 
-20°C. Stock solution was then diluted with PBS for a final concentration of 20 nM.  20 nM 
TAM was administered in each experiment to appropriate wells, each containing 50,000 
cells/mL.  
2.4(c) Secoisolariciresinol diglucoside (SDG) 
A stock solution of SDG dissolved in ethanol and water (1 mg SDG, 400 uL ethanol, 1 
mL of water) was held in dark storage at 0°C.  Stock solution was then diluted with PBS for a 
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final concentration of 100 uM, which was administered in each experiment to appropriate wells 
containing 50,000 cells/mL.  
2.5 Statistical Analyses 
 Data from the experiments were expressed as mean +/- SEM, with statistical analysis 
performed using one-way ANOVA on Microsoft Excel.  A p-value of 0.05 was used to as the 
criteria for statistical significance, using 3 biological replicates to increase the validity of the 
data. 
 
3. Results and Discussion 
3.1 Estrogen Response  
In order to perform experiments that analyze SDG’s and TAM’s effects on T47D cells, 
we first needed to ensure the cells were estrogen responsive.  The results from the E2 positive 
control experiment showed that at an estrogen concentration of 20 nM, T47D cells showed 
maximal increase in proliferation with less responsiveness as concentrations decreased, as shown 
in Figure 1 below.  These results indicate that the cells are most responsive to E2 at a 
concentration of 20 nM; therefore, this is the concentration that we proceeded to utilize in further 
experiments when treating with E2. 
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 “Percent control” values were calculated for this experiment and for all following 
experiments because it allowed us to calculate a standard deviation if multiple tests were run, 
minimizing variation in absolute counts between individual tests. 
3.2 Co-administration of TAM and SDG on T47D Cells  
T47D cells were initially treated with increasing SDG concentrations from 1 uM to 100 
uM, combined with 20 nM E2, in order to determine the optimal concentration of SDG for 
treatments.  Figure 2 shows that growth inhibition from SDG peaked at 100 uM, while greater 
concentrations led to minimal difference in inhibition.  This provided the basis of administering 
100 uM SDG concentration for further experiments.  It is important to note that the optimal 
concentration was based on the average inhibitory response for the triplicate trials; while the 
error bars shown in Figure 2 overlap with the other treatments and the interpretation that 100 uM 
showed the highest inhibitory ability is not definite, the data here support such an interpretation. 
Figure 1 (left): 
Proliferation of T47D cells 
when administered β-
estradiol.  Data represents 
counts of cells growing in 
1mL of media on a 24-well 
plate following 48hrs 
incubation.   
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Figure 2: Dosage response for SDG compared to negative control (only T47D cells) ranging 
from 1 uM to 1000 uM.  Peak growth inhibition was found at 100 uM SDG. 
 
In order to determine the effects of SDG and TAM on T47D inhibition, cells were treated 
with either estrogen alone (positive control), estrogen + tamoxifen, estrogen + SDG, estrogen + 
SDG + TAM, and cells + EtOH (negative control).  The wells were set up in triplicates and the 
experiment was replicated three times.  Figure 3 compiles this data into one graph.  All 
treatments administered with SDG, TAM, or a combination of both resulted in significant 
inhibition compared to that of the positive control (p < 0.01, N = 3, see Figure 3).  Combination 
of TAM and SDG treatments showed the greatest cell inhibition compared to the positive control 
(p < 0.01, see Figure 3), but was not significantly different to treatments of just TAM or SDG 
alone.  In comparison to the drug treatments, cells treated with only E2 continued to show the 
highest cell counts, as expected.  This data indicates that there is a significant increase in 
inhibition of E2 induced T47D cell proliferation when treatments of SDG and TAM are 
administered individually or in combination, but not enough evidence is found to conclude 
whether there is a synergistic effect of combination treatments vs. individual treatments. 
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Figure 3: Percent control calculations for each cell treatment based on the control wells 
containing cells only. Experiment was repeated 3 times and average percent control was 
calculated.  Standard error bars are shown on the data bars which contain treatments.  Since the 
data are being compared to the average control, the control has no standard deviation.  Cells + 
EtOH also has no standard deviation considering the test was run only once. 
 
The vehicle control treatment, consisting of cells treated with just 5 nM EtOH, showed 
similar counts to the untreated control (cells that were not treated with any drugs) and were not 
significantly different, indicating that the addition of EtOH had no anti-proliferative effect on the 
cells.  The purpose of administering such a small concentration of EtOH to cells was to ensure 
that the decrease in proliferation may not have been due to the EtOH which was used to dissolve 
the three drugs.  The maximum concentration of ethanol in cell culture that does not cause toxic 
damage to the cells is approximately 5% (Tapani et. al, 1996).  Since the maximum 
concentration of ethanol that ended up in the wells after all dilutions were performed was only 5 
nM, approximately 5.0 x 10-9 percent of the final volume consisted of pure ethanol.  This 
percentage is much less than the limit of 5% of the total volume, it can be concluded that ethanol 
was not the primary cause of anti-proliferation. 
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The data in Figure 3 suggests that the combination of these two drugs on cells that are 
exposed to estrogen further suppresses growth compared to either treatment alone by a factor of 
7% regarding SDG and 10.3% regarding TAM, but this was not significant.  However, it is 
important to note that the standard error bars for both of these suggestions are overlapping.  
Although averages were used in data analysis, there is not enough statistical evidence to 
conclude that combination treatments of SDG and TAM have greater inhibitory effects than 
either drug alone.  However, the results obtained are promising; future experiments are required 
to continue to explore this topic.  Furthermore, cell counts shown in Figure 3 of TAM treatment, 
SDG treatment, and combination treatment were much lower compared to that of the untreated 
control, indicating a possibility of cell apoptosis.  This claim would be the basis of future 
experiments involving SDG, TAM, and proteins that are released from cells when cell apoptosis 
is triggered. 
 
3.3 Luciferase Assay  
 In order to determine the mechanism of TAM and SDG inhibition on T47D growth, a 
luciferase assay was performed.  The luciferase reporter assay was used to determine whether 
SDG is acting through an estrogen receptor or via a different metabolic pathway when inhibiting 
cellular proliferation.  The T47DKBluc cells are tagged at their estrogen receptors with a 
construct of estrogen response elements, promoters, and luciferase, allowing them to luminesce 
in response to 17-beta-estradiol.  It is expected that the addition of E2 and TAM will induce 
fluorescence, because it has been shown through prior research that estrogen and Tamoxifen act 
through both the alpha and beta estrogen receptor (ER).  The addition of SDG explored whether 
it also acted through the ER, by determining whether the cells luminesce at a similar emission as 
those treated with E2 and TAM.  The results from this experiment are shown below. 
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Cells were administered either E2, TAM, or SDG, along with a vehicle control.  The 
experiment was repeated in triplicates in order to calculate statistical significance.  Emission of 
the “cells + SDG” treatment and the “cells + TAM” treatment were significantly greater than that 
of just cells alone (p-value < 0.05, see Figure 4a and 4b), and were not significantly different 
than the positive control of just “cells + E2”.  Since the positive control would have maximum 
luminescence due to the binding of the ER, there is evidence to suggest that both SDG and TAM 
are acting through an estrogen receptor when inhibiting cellular proliferation.  The luminescence 
of cells that were treated with E2 was 639 units, and that of the cells treated with TAM was 754 
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Figure 4a (above) and 4b 
(left): Luciferase reporter 
assay data.  Standard error 
bars are shown.  Percent 
control is shown in panel A.  
The numerical values 
represent luminescence units 
of RLU/mL in panel B. 
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units, meaning that both E2 and TAM act through the receptor.  The luminescence of cells that 
were treated with SDG fell close by that of the control treatment with a value of 685 units.  This 
suggests that SDG does act through the ER.  However, which receptor (alpha or beta) it is acting 
through is still unclear and requires further experimentation.  It is possible that this ER binding is 
not the mechanism responsible for the decrease in cell proliferation.  Experimentation with 
antagonizing both the alpha and beta receptors would have provided further insight on this 
information.   
 
4. Future Experiments 
4.1 Immunoblots 
 In order to determine if SDG and TAM are acting through another metabolic pathway 
that is triggering cell apoptosis, an immunoblot would be performed using antibodies to probe 
for apoptosis related proteins that would be upregulated, such as caspase 3. (Papaliagkas et. al, 
2007).  If these proteins appeared on the blot and were upregulated compared to controls along 
with either SDG or TAM, then there would be evidence to conclude that SDG or TAM (or both) 
are acting through another metabolic pathway to trigger cell apoptosis, combined with 
antagonizing the estrogen receptor. This experiment only provides evidence that SDG and TAM 
are acting through the apoptosis pathway, but does not necessarily identify if the decreased cell 
numbers are from the estrogenic pathway or the apoptosis pathway.  It is hypothesized that both 
SDG and TAM are acting through both the apoptosis and estrogen pathway, and the results 
would show that apoptosis-indicating proteins such as caspase-3 would appear upregulated in the 
gel, along with other cell cycle regulatory proteins such as p21 (Porter & Jänicke, 1999).  
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 Immunoblotting will be used to search for two proteins of interest: caspase-3 and p21. 
Concentration of proteins from lysed cells would be calculated, and samples would be vortexed 
to denature proteins in a 95°C temp block for 5 minutes.  The samples would then be loaded onto 
12% acrylamide 10-well Mini Protean Precast Gels (Bio-Rad) based on the amount of total 
protein for all samples.  Gel electrophoresis would be conducted at 200 V until the dye runs off, 
and the gel would be cut with a razor to remove well lanes and dye runoff.  The gel would then 
be put in a transfer buffer.  Polyvinylidene difluoride (PVDF) membrane would be wetted with 
methanol, then soaked in the transfer buffer and placed on top of the gel along with filter paper.  
Following transfer, PVDF membranes would be cut in half using a razor and put in a blocking 
solution of 1% low fat instant dried milk in 1X Tris-Buffered Saline with 0.1% Tween-20 (TBS-
T).  Primary antibody dilutions of 1:1000 of caspase-3 p17 (sc-271028-Santa-Cruz 
Biotechnology) and p21 would be made in 1X TBS-T and kept cold.  The antibodies would then 
be incubated and washed on a rocking platform.  Secondary antibody, IgGk BP-HRP (sc-
516102-Santa-Cruz Biotechnology), would be diluted by 1:5000 in 1X TBS-T.  Immunoblots 
would be incubated in secondary antibody for 1 hour at room temperature on a rocking platform, 
and then stained with colorimetric 1-Step Ultra TMB Blotting-Solution (ThermoFisher 
Scientific) for 5-30 minutes or until bands develop.  Blots would finally be imaged using the 
ChemiDoc XRS Gel Photo Documentation System (BioRad).  
 Using image J, we would assess the density of bands in the treated and control lanes. We 
would be looking for increased density for bands of caspase-3 and p21 that would indicate to us 
that these proteins were upregulated by either SDG or TAM in T47D cells.  
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4.2 Receptor Identification  
 Although the data suggest that the anti-proliferation effects of SDG and TAM are due to 
the binding of an estrogen receptor, it does not conclude that the anti-proliferation observed is 
strictly due to this binding.  Therefore, an experiment that antagonizes the α- or β-receptors of 
T47D-KBluc cells is appropriate to conduct.  According to the literature, TAM is known to work 
through ER-α in order to competitively inhibit binding of estrogen to the receptor.  However, 
there is not enough evidence in the literature to indicate to which receptor SDG binds.  
Therefore, T47D-KBluc cells where either the α- or β-receptor individually is inhibited would be 
treated with SDG and TAM to determine through which receptor each drug may be functioning.  
Following a similar experimental setup to that seen in Figure 4, T47D-KBluc cells would be 
cultured in a charcoal 96-well plate.  A charcoal-plate would be used to remove steroid-related 
materials from the medium.  However, before the addition of SDG, TAM, and E2, α- and β-
receptor antagonists would be added in separate experiments.  SDG, TAM, and E2 would be 
administered to both cell lines in triplicates, and a luciferase assay would be performed.  It is 
hypothesized that since TAM acts primarily through ER-α, SDG would bind to ER-β in order to 
achieve the synergistic effects displayed in Figure 3.  Essentially, luminescence levels of cells 
when treated with SDG that are α-receptor-inhibited would be high compared to that of the 
vehicle control.   
 19 
References 
 
Bowers, L. W., Lineberger, C. G., Ford, N. A., Rossi, E. L., Punjala, A., Camp, K. K., 
Kimler, B. K., Fabian, C. J., & Hursting, S. D. (2019). The flaxseed lignan secoisolariciresinol 
diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary 
tumor growth. Breast cancer research and treatment, 173(3), 545–557. 
https://doi.org/10.1007/s10549-018-5021-6 
 
BPS Bioscience Inc. (2020). ONE-Step™ Luciferase Assay System. (2020). Retrieved 
from https://bpsbioscience.com/one-step-luciferase-assay-system-60690 
 
Celojevic, D., Petersen, A., Karlsson, J.-O., Behndig, A., & Zetterberg, M. (2011, July 
20). Effects of 17β-estradiol on proliferation, cell viability and intracellular redox status in native 
human lens epithelial cells. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154121/.  
 
Chen, Jianmin, and Lilian U. Thompson. “Lignans and Tamoxifen, Alone or in 
Combination, Reduce Human Breast Cancer Cell Adhesion, Invasion and Migration in Vitro.” 
Breast Cancer Research and Treatment, vol. 80, no. 2, 2003, pp. 163–170., 
doi:10.1023/a:1024513815374. 
 
Duursen, Majorie B.m. Van, et al. “Phytoestrogens in Menopausal Supplements Induce 
ER-Dependent Cell Proliferation and Overcome Breast Cancer Treatment in an in Vitro Breast 
Cancer Model.” Toxicology and Applied Pharmacology, vol. 269, no. 2, 2013, pp. 132–140., 
doi:10.1016/j.taap.2013.03.014. 
 
Erna Tapani, M. Taavitsainen, K. Lindros, T. Vehmas & E. Lehtonen (1996) Toxicity of 
Ethanol in Low Concentrations, Acta Radiologica, 37:6, 923-926 
 
Helguero, Luisa A, et al. “Estrogen receptors alpha and beta differentially regulate 
proliferation and apoptosis of the normal murine mammary epithelial cell line HC11.” Nature, 
vol. 24, 2005, pp. 6605–6616. 
 
Kishikawa, Hiroko, et al. “Targeting Angiogenin in Therapy of Amyotropic Lateral 
Sclerosis.” Expert Opinion on Therapeutic Targets, vol. 12, no. 10, 2008, pp. 1229–1242., 
doi:10.1517/14728222.12.10.1229. 
 
Lamartiniere, Coral A. “Protection against Breast Cancer with Genistein: a Component of 
Soy.” The American Journal of Clinical Nutrition, vol. 71, no. 6, 2000, 
doi:10.1093/ajcn/71.6.1705s. 
 
Lindahl, G., et al. “Tamoxifen, Flaxseed, and the Lignan Enterolactone Increase Stroma- 
and Cancer Cell-Derived IL-1Ra and Decrease Tumor Angiogenesis in Estrogen-Dependent 
Breast Cancer.” Cancer Research, vol. 71, no. 1, 2010, pp. 51–60., doi:10.1158/0008-5472.can-
10-2289. 
 
 20 
Liu, Bolin, et al. “Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated 
Mammary Tumor Prevention.” Cancer Research, American Association for Cancer Research, 1 
Feb. 2005, cancerres.aacrjournals.org/content/65/3/879. 
 
Montes-Grajales, Diana, et al. “Phytoestrogens and Mycoestrogens Interacting with 
Breast Cancer Proteins.” Steroids, vol. 134, 2018, pp. 9–15., doi:10.1016/j.steroids.2018.03.010. 
 
Nurrochmad, Arief, et al. “Combination of Low-Concentration of Novel Phytoestrogen 
(8,9)-Furanyl-Pterocarpan-3-Ol from Pachyrhizus Erosus Attenuated Tamoxifen-Associated 
Growth Inhibition on Breast Cancer T47D Cells.” Asian Pacific Journal of Tropical 
Biomedicine, vol. 3, no. 11, 2013, pp. 847–852., doi:10.1016/s2221-1691(13)60167-7. 
 
Papaliagkas, V., Anogianaki, A., Anogianakis, G., & Ilonidis, G. (2007, July). The  
proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Retrieved May 
07, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658792/  
 
Peng, Yuan, et al. “Angiogenin Interacts with Ribonuclease Inhibitor Regulating 
PI3K/AKT/MTOR Signaling Pathway in Bladder Cancer Cells.” Cellular Signalling, vol. 26, no. 
12, 2014, pp. 2782–2792., doi:10.1016/j.cellsig.2014.08.021. 
 
Porter, A., & Jänicke, R. (1999, February). Emerging roles of caspase-3 in apoptosis.  
Retrieved May 07, 2020, from https://www.ncbi.nlm.nih.gov/pubmed/10200555  
 
Sporn, M. B. (1970, January 1). Agents for Chemoprevention and Their Mechanism of 
Action. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK12522/. 
 
Swann, Ruth, et al. “The DietCompLyf Study: A Prospective Cohort Study of Breast 
Cancer Survival and Phytoestrogen Consumption.” Maturitas, vol. 75, no. 3, 2013, pp. 232–240., 
doi:10.1016/j.maturitas.2013.03.018. 
 
Thermo Fisher Scientific Inc. (2020). Charcoal Stripped Fetal Bovine Serum. (n.d.). 
Retrieved from https://www.thermofisher.com/us/en/home/life-science/cell-culture/mammalian-
cell-culture/fbs/specialty-serum/charcoal-stripped-fbs.html  
 
Velentzis, Louiza S., et al. “Do Phytoestrogens Reduce the Risk of Breast Cancer and 
Breast Cancer Recurrence? What Clinicians Need to Know.” European Journal of Cancer, vol. 
44, no. 13, 2008, pp. 1799–1806., doi:10.1016/j.ejca.2008.05.019. 
 
Wilson, V. S., Bobseine, K., & Gray, L. E. (2004, September). Development and 
characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for 
the detection of estrogen receptor agonist and antagonists. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/15166400  
 
Zafar, Atif, et al. “Cytotoxic Activity of Soy Phytoestrogen Coumestrol against Human 
Breast Cancer MCF-7 Cells: Insights into the Molecular Mechanism.” Food and Chemical 
Toxicology, vol. 99, 2017, pp. 149–161., doi:10.1016/j.fct.2016.11.034. 
